Genetic variability in E6, E7 and L1 protein of HPV81 from HIV-1 positive women in Italy

New Microbiologica

Volumn 33, Issue 1, 2010, Pages 25-35

  Minosse, Claudia ^a   Garbuglia, Anna R ^a   Lapa, Daniele ^a   Sias, Catia ^a   Zaniratti, Maria S ^a   Capobianchi, Maria R ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

E6 gene; E7 gene; Human papillomavirus; L1 gene; PCR sequencing; Variants

Indexed keywords

CAPSID PROTEIN; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; ONCOPROTEIN; PROTEIN E7;

ADULT; ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; ARTICLE; CHEMISTRY; CLASSIFICATION; FEMALE; GENETIC VARIABILITY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; ITALY; MIDDLE AGED; MOLECULAR GENETICS; PAPILLOMAVIRUS INFECTION; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; VIROLOGY;

ADULT; ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; CAPSID PROTEINS; FEMALE; GENETIC VARIATION; HIV SEROPOSITIVITY; HUMANS; ITALY; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS;

EID: 77950277164     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. BERNARD H.U. (1994). Convolution of papillomaviruses with human populations. Trends Microbiol 2 (4), 140-143.
2. BERNARD H.U., CALLEJA-MACIAS I.E., DUNN S.T. (2006). Genome variation of human papillomavirus types: phylogenetic and medical implications. Int. J. Cancer. 118 (5), 1071-1076.
3. BOSCH EX., MANOS M.M., MUNOZ N., SHERMAN M., JANSEN A.M., PETO J., SCHIFFMAN M.H., MORENO V., KURMAN R., SHAH K.V. (1995). Prevalence of human papillomavirus in cervical cancer a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer. Inst. 87 (11), 796-802.
4. BOSCH EX., LORINCZ A., MUÑOZ N., MEIJER C.J., SHAH K.V. (2002). The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 (4), 244-265.
5. CALLEJA-MACIAS I.E., KALANTARI M., ALLAN B., WILLIAMSON A.L., CHUNG L.P., COLLINS R.J., ZUNA R.E., DUNN S.T., ORTIZ-LOPEZ R., BARRERA-SALDAÑA H.A., CUBIE H.A., CUSCHIERI K., VILLA L.L., BERNARD H.U. (2005a). Papillomavirus subtypes are natural and old taxa: phylogeny of human papillomavirus types 44 and 55 and 68a and -b. J. Virol. 79 (10), 6565-6569.
6. CALLEJA-MACIAS I.E., VILLA L.L., PRADO J.C., KALANTARI M., ALLAN B., WILLIAMSON A.L., CHUNG L.P., COLLINS R.J., ZUNA R.E., DUNN S.T., CHU T.Y., CUBIE H.A., CUSCHIERI K., VON KNEBEL-DOEBERITZ M., MARTINS C.R., SANCHEZ G.I., BOSCH F.X., MUNOZ N., BERNARD H.U. (2005b). Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J. Virol. 79 (21), 13630-13640.
7. CERQUEIRA D.M., DE S. MORAES D., CAMARA G.N., AMARAL F.A., OYAMA CN., DOS SANTOS MQ, MARTINS CR. (2007). High HPV genetic diversity in women infected with HIV-I in Brazil. Arch. Virol. 152 (1), 75-83.
8. CHRISTENSEN N.D., REED C.A., CLADEL N.M., HALL K., LEISEROWITZ G.S. (1996). Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology. 224 (2), 477-486.
9. COMBITA A.L., TOUZE A., BOUSARGHIN L., CHRISTENSEN N.D., COURSAGET P. (2002). Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J. Virol. 76 (13), 6480-6486.
10. ELLERBROCK T.V., CHIASSON M.A., BUSH T.J., SUN X.W., SAWO D., BRUDNEY K., WRIGHT T.C. JR. (2000). Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 283 (8), 1031-1037.
11. FARTHING A. J., VOUSDEN K.H. (1994). Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol. 2 (5), 170-174.
12. GAGNON S., HANKINS C., TREMBLAY C., POURREAUX K., FOREST P., ROUAH F., COUTLÉE F. (2005). The Canadian Women's HIV Study Group, François Coudée. Polymorphism of human papillomavirus type 31 isolates infecting the genital tract of HIV-seropositive and HIV-seronegative women at risk for HIV infection. J. Med. Virol. 75 (2), 213221.
13. GARBUGLIA A.R., CARLETTI E, MINOSSE C., PISELLI P., ZANIRATTI M.S., SERRAINO D., CAPOBIANCHI M.R. (2007). Genetic variability in E6 and E7 genes of human papillomavirus -16, -18, -31 and -33 from HIV-1-positive women in Italy. New Microbiol. 30 (4), 377-382.
14. HARPER D.M., FRANCO E.L., WHEELER C., FERRIS D.G., JENKINS D., SCHUIND A., ZAHAF T., INNIS B., NAUD P., DE CARVALHO N.S., ROTELI-MARTINS C.M., TEIXEIRA J., BLATTER M.M., KORN A.P., QUINT W., DUBIN G. (2004). GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 364 (9447), 1757-1765.
15. Ho L., CHAN S.Y, CHOW V., CHONG T., TAY S.K., VILLA L.L., BERNARD H.U. (1991). Sequence variants of human papillomavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree. J. Clin. Microbiol. 29 (9), 1765-1772.
16. KOUTSKY L.A., AULT K.A., WHEELER C.M., BROWN D.R., BARR E., ALVAREZ F.B., CHIACCHIERINI L.M., JANSEN K.U. (2002). Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (21), 1645-1651.
17. LILLo F.B. (2005). Human papillomavirus infection and its role in the genesis of dysplastic and neoplastic lesions of the squamous epithelia. New Microbiol. 28(2), 111-118.
18. LORINCZ A.T., REID R., JENSON A.B., GREENBERG M.D., LANCASTER W., KURMAN R.J. (1992). Human papill omavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 79 (3), 328-337.
19. MANOS M.M., TING Y., WRIGHT D.K., LEWIS A.J., BROKER T.R., WOLINSKY S.M. (1989). Use of polymerase chain reaction amplification for the detection of genital human papillomavirus. Cancer Cells. 7, 209-214.
20. MENZO S., MARINELLI K., BAGNARELU P., ROLLA S., CLEMENTI M. (2007). Human papillomavirus infections: new perspectives for prevention and treatment. New Microbiol 30 (3), 189-212.
21. MUNOZ N., BOSCH F.X., DE SANJOSÉ S., HERRERO R., CASTELLSAGUÉ X., SHAH K.V, SNIJDERS P.J., MEIJER C.J. (2003). International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl J. Med. 348 (6), 518-527.
22. MUNOZ N., CASTELLSAGUÉ X., DE GONZÁLEZ A.B., GISSMANN L. (2006). Chapter 1: HPV in the etiology of human cancer. Vaccine. 24 (Suppl 3), S3/1-10.
23. RIVA E., SERRAINO D., PIERANGELI A., BAMBACIONI F., ZANIRATTI S., MINOSSE C., SELLERI M., BUCCI M., SCAGNOLARI C., DEGENER A.M., CAPOBIANCHI M.R., ANTONELLI G., DIANZANI F., THE ROMAN PAPILLOMAVIRUS STUDY GROUP. (2007). Markers of human papillomavirus infection and their correlation with cervical dysplasia in human immunodeficiency virus-positive women. Clin. Microbiol. Infect. 13 (1), 94-97.
24. RONCO G., GHISETTI V., SEGNAN N., SNUDERS P.J., GILLIOTos A., MEUER C.J., MERLETTI F., FRANCESCHI S. (2005). Prevalence of human papillomavirus infection in women in Turin, Italy. Eur. J. Cancer. 41 (2), 297-305.
25. SYCURO L.K., XI L.E, HUGHES J.P., FENG Q., WINER R.L., LEE S.K., O'REILLY S., KIVIAT N.B., KOUTSKY L.A. (2008). Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J. Infect. Dis. 198 (7), 971-978.
26. STEWART A.C., ERIKSSON A.M., MANOS M.M., MUNOZ N., BOSCH F.X., PETO J., WHEELER C.M. (1996). Intratype variation in 12 human papillomavirus types: a worldwide perspective. J. Virol. 70 (5), 3127-3136.
27. TORNESELLO M.L., DURATURO M.L., GlORGI-ROSSI P., SANSONE M., PICCOLI R., BUONAGURO L., BUONAGURO EM. (2008a). Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. J. Gen. Virol. 89 (Pt 6), 1380-1389.
28. TORNESELLO M.L., BUONAGURO L. Izzo S., LOPEZ G., VEGA X., MALDONADO REYES C.F., BUONAGURO F.M. (2008b). A pilot study on the distribution of human papillomavirus genotypes and HPV-16 variants in cervical neoplastic lesions from Ecuadorian women. J. Med. Virol. 80 (11), 1959-1965.
29. VILLA L.L., COSTA R.L., PETTA C.A., ANDRADE R.P., AULT K.A., GIUUANO A.R., WHEELER C.M., KOUTSKY L.A, MALM C., LEHTINEN M., SKJELDESTAD F.E., OLSSON S.E., STEINWALL M., BROWN D.R., KURMAN R.J., RONNETT B.M., STOLER M.H., FERENCZY A., HARPER D.M., TAMMS G.M., Yu J., LUPINACCI L., RAILKAR R., TADDEO F.J., JANSEN K.U, ESSER M.T., SINGS H.L., SAAH A.J., BARR E. (2005). Prophylactic quadrivalent human papillomavirus (types 6,11,16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (5), 271-278.
30. WALBOOMERS J.M., JACOBS M.V., MANOS M.M., BOSCH F.X., KUMMER J.A., SHAH K.V., SNIJDERS P.J., PETO J., MEIJER C.J., MUNOZ N. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1), 12-19.
31. WEINBERG R.A. (1991). Tumor suppressor genes. Science. 254 (5035), 1138-1146.
32. XI L.F., DEMERS G.W., KOUTSKY L.A., KTVIAT N.B., KUYPERS J., WATTS D.H., HOLMES K.K., GALLOWAY D.A. (1995). Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J. Infect. Dis. 172 (3), 747-755.
33. ZENG L., YU S.Y., HU Z.H., ZHANG J. (2008). Polymorphisms of human papillomavirus type 81 L1 gene in patients with cervical lesions in Guangdong. Nan. Fang. Yi Ke Da Xue Xue Bao. 28 (12), 2210-2212.